NVCT
What one share of Nuvectis Pharma holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We seek to develop drug candidates in the precision medicine space, and our processes for selection and clinical development of drug candidates are based on scientific data into cancer-promoting factors, as well as our understanding of the clinical landscape and regulatory requirements.
Nuvectis Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.30 |
|---|---|
| Cash and investments | $0.83 |
| Book value | $0.34 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$3.02 | — | −$2.23 | — | −$2.44 |
| 2022 | — | −$1.51 | — | −$1.07 | $0.00 | $0.94 |
| 2023 | — | −$1.43 | — | −$1.03 | $0.00 | $0.70 |
| 2024 | — | −$1.11 | — | −$0.72 | $0.00 | $0.50 |
| 2025 | — | −$1.32 | — | −$0.73 | $0.00 | $0.72 |